Nuvectis Pharma (NVCT) Research & Development (2021 - 2026)
Nuvectis Pharma (NVCT) reported Research & Development of $4.1 million for Q1 2026, up 11.58% on a YoY basis from $3.7 million in Q1 2025, and down 19.27% sequentially from $5.1 million in Q4 2025.
Nuvectis Pharma (NVCT) Research & Development (2021 - 2026) Analysis & Trends
Nuvectis Pharma (NVCT) has 6 years of Research & Development data on file, last reported at $4.1 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 11.58% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $18.6 million (up 33.3% YoY), and the FY2025 full-year result was $18.2 million, up 40.52% from the prior year.
- Research & Development slipped to $4.1 million in Q1 2026, from $5.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $5.8 million in Q3 2025 to a low of $865000.0 in Q1 2022.
- A 5-year average of $3.7 million and a median of $4.1 million in 2026 frame the typical range for Research & Development.
- Peak annual rise in Research & Development reached 284.35% in 2022, while the deepest fall reached 40.99% in 2022.
- Tracing NVCT's Research & Development over 5 years: stood at $4.4 million in 2022, then fell by 3.0% to $4.3 million in 2023, then climbed by 5.42% to $4.5 million in 2024, then increased by 13.12% to $5.1 million in 2025, then fell by 19.27% to $4.1 million in 2026.
- Business Quant data shows NVCT's Research & Development at $4.1 million in Q1 2026, $5.1 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Nuvectis Pharma | 471.80 Mn | 471.80 Mn | - | 4.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.11 Mn |
| Dec 31, 2025 | 5.09 Mn |
| Sep 30, 2025 | 5.77 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 3.68 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Sep 30, 2024 | 2.82 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 4.27 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 4.26 Mn |
| Mar 31, 2023 | 2.37 Mn |
| Dec 31, 2022 | 4.40 Mn |
| Sep 30, 2022 | 4.52 Mn |
| Jun 30, 2022 | 2.51 Mn |
| Mar 31, 2022 | 865,000.00 |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 4.16 Mn |
| Jun 30, 2021 | 4.25 Mn |